Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer ModelingJuliann Chmielecki, William Pao, Agnès Viale et al.|Science Translational Medicine|2011Cited by 530
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <i>EGFR</i> -Mutant Lung CancerAdam J. Schoenfeld, Helena A. Yu, Joseph M. Chan et al.|Clinical Cancer Research|2020Cited by 381
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung CancersMorana Vojnic, Marc Ladanyi, Daisuke Kubota et al.|Journal of Thoracic Oncology|2019Cited by 97
HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell TumorTom Zhang, Romel Somwar|Clinical Cancer Research|2024Cited by 16
Establishment of multiple novel patient-derived models of desmoplastic small round cell tumor enabling functional characterization of ERBB pathway signaling and pre-clinical evaluation of a novel targeted therapy approachRoger S. Smith, Romel Somwar|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 4